Business Wire (Apr 3, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
549 people get OMPI articles and Market Currents by email alert.
Get email alerts on OMPI »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Apr 2, 2013)
-
-
-
Business Wire (Mar 21, 2013)
-
-
-
Business Wire (Mar 14, 2013)
-
Business Wire (Jan 30, 2013)
-
-
-
Business Wire (Dec 10, 2012)
-
-
Business Wire (Nov 28, 2012)
-
-
Business Wire (Nov 21, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
Closer Look: OMPI's Acquisition Rumors And Price TargetsM. E. Garza • Wed, May 9, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Sector Detector: Against The Odds, Markets Are Looking More BullishScott Martindale • Thu, Jul 12, 2012
-
Obagi Medical Products, Inc. Q2 2010 Earnings Call TranscriptFri, Aug 6, 2010
-
Obagi Medical Products, Inc. Q1 2010 Earnings Call TranscriptSat, May 8, 2010
-
Obagi Medical Products, Inc. Q1 2009 Earnings Call TranscriptThu, May 7, 2009
-
Obagi Medical Products, Inc. Q4 2008 Earnings Call TranscriptThu, Mar 5, 2009 • 1 Comment
-
Obagi Medical Products, Inc. Q3 2008 Earnings Call TranscriptThu, Nov 20, 2008
-
Obagi Medical Products, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 11, 2008
-
Obagi Medical Products, Inc. Q1 2008 Earnings Call TranscriptMon, May 5, 2008
-
Obagi Medical Products, Inc. Q4 2007 Earnings Call TranscriptMon, Mar 3, 2008 • 5 Comments
-
Obagi Medical Products Q3 2007 Earnings Call TranscriptTue, Nov 13, 2007 • 4 Comments
-
at MarketWatch.com (Apr 3, 2013)
-
Business Wire (Apr 2, 2013)
-
Business Wire (Mar 21, 2013)
-
Business Wire (Mar 14, 2013)
-
Business Wire (Jan 30, 2013)
-
Business Wire (Dec 10, 2012)
-
Business Wire (Nov 28, 2012)
-
Business Wire (Nov 21, 2012)
-
Business Wire (Nov 14, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 16, 2012)
-
Business Wire (Aug 29, 2012)
-
Business Wire (Aug 16, 2012)
-
at CNBC.com (Aug 3, 2012)
-
Business Wire (Aug 2, 2012)
-
Business Wire (Jul 16, 2012)
OMPI vs. ETF Alternatives
Company Description
The Company was founded as WorldWide Product Distribution, Inc. (“Worldwide”) in 1988. OMP Acquisition Corporation was incorporated in California in October 1997 to purchase substantially all of the assets and to assume the accounts payable and related operating liabilities of WorldWide and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, April 22, 12:26 PM Valeant Pharmaceuticals (VRX -1.4%) receives U.S. antitrust approval for its $24/share acquisition of Obagi Medical (OMPI). The deal now needs the authorization of the Antimonopoly Committee of Ukraine. (PR) Comment! [Healthcare]
-
Monday, April 8, 9:10 AM
Premarket gainers: LUFK +38%. BSDM +34%. BCRX +18%. UNXL +15%. GOL +10%. TSL +7%.
Losers: OMPI -6%. DCTH -5%. Comment! [On the Move] - Monday, April 8, 8:18 AM Obagi Medical (OMPI) falls before the bell after German drug maker Merz says it will not up the ante on Valeant Pharmaceuticals (VRX) in what was set to become a bidding war for OMPI. Merz, which called itself "a disciplined buyer" this morning, topped Valeant's original $19 per share offer last week, but will now yield to Valeant's sweetened offer of $24. OMPI shares -5.6% premarket. Comment! [Healthcare, M&A, On the Move]
-
Wednesday, April 3, 9:10 AM
Premarket gainers: CALL +14%. CONN +10%. ZNGA +10%. ASTX +10%. UNXL +9%. AWRE +9%. OMPI +9%. NVAX +9%. ALXA +8%. MHR +7%. NFX +6%.
Losers: MSPD -19%. GPN -7%. 3 Comments [On the Move] - Wednesday, April 3, 8:12 AM Bidding war on: Valeant Pharmaceuticals (VRX) increases its offer for Obagi Medical (OMPI) to $24 a share in cash, a day after Merz Pharmaceuticals proposed $22. That bid had trumped Valeant's original offer of $19.75. Obagi has accepted Valeant's new proposal, which has sent the former's shares up 8.4% to $24.80. Comment! [Breaking News, M&A, Healthcare, On the Move]
-
Tuesday, April 2, 9:10 AM
Premarket gainers: BGCP +47%. OMPI +14%. HUM +10%. NUAN +9%. URBN +6%.
Losers: NAT -12%. AFFY -7%. Comment! [On the Move] - Tuesday, April 2, 8:12 AM Merz Pharmaceuticals offers $22 a share for Obagi (OMPI) and trumps Valeant's (VRX) bid of $19.75 , which valued Obagi at $360M. Merz says it has the money to pay for the deal and doesn't need to carry out further due diligence, as it was already in talks to buy Obagi when the Valeant deal was announced. Obagi surges 15.2% to $22.70. 2 Comments [M&A, On the Move, Healthcare]
- Thursday, March 21, 2:20 PM Cantor Fitzgerald says it's lowering its rating on Obagi Medical Products (OMPI +0.2%) from Buy to Hold on the back of yesterday's merger announcement with Valeant Pharmaceuticals (VRX +0.2%). Cantor says the deal is generally in line with other historical deals in the dermatology space, and after speaking with management it believes the deal has been fully shopped and there aren't likely to be any competing bids. Comment! [M&A, Healthcare]
-
Wednesday, March 20, 12:45 PM
Midday top 10 gainers: OMPI +28%. AFFY +18%. MTSL +13%. NPD +12%. CHYR + 12%. GEVO +12%. WSM +11%. BIOF +10%. AIR +9%. PPHM +8%.
Midday top 10 losers: ATOS -18%. LIVE -15%. MXWL -15%. CHKR -14%. ECT -12%. CIG -13%. SGOC -12%. FFEX -11%. ABCD -11%. OTIV -9%. Comment! [On the Move] -
Wednesday, March 20, 9:10 AM
Premarket gainers: OMPI +28%. GEVO +17%. CIE +7%. WSM +6%. ADBE +6%. BBRY +5%.
Losers: ECT -9%. CIG -9%. 7 Comments [On the Move] - Wednesday, March 20, 8:13 AM Valeant Pharmaceuticals (VRX) has agreed to acquire Obagi Medical Products (OMPI) for $360M, with the $19.75/share offer representing a 42% premium to Obagi's closing price on Thursday last week, a day before it released its 2012 earnings results. (PR) Comment! [Healthcare, M&A, Breaking News]
- Friday, March 15, 11:39 AM Obagi Medical (OMPI +7.7%) moves up today after topping Q4 estimates late yesterday. Looking forward, the company sees FY13 earnings of $0.80 to $0.84 per share on $126M to $130M. The Street is at $0.88 per share and $128.31M in revenue. Cantor Fitzgerald upgraded the shares to Buy on the back of the report and raised its price target from $15.00 to $19.00, noting a 50% probability of a takeout in the $21 range. 1 Comment [Healthcare, Earnings, On the Move, M&A]
- Thursday, March 14, 4:28 PM Obagi Medical (OMPI): Q4 EPS of $0.15 misses by $0.06. Revenue of $30.3M beats by $0.24M. (PR) Comment! [Earnings, Breaking News]
- Thursday, March 14, 12:10 AM Notable earnings after Thursday ’s close: ANAC, ARO, BCEI, COSI, CPE, EGY, FXEN, HOGS, KKD, MCP, OMPI, STEC, ULTA, ZUMZ Comment! [Earnings]
- Wednesday, March 13, 5:35 PM Notable earnings after Thursday ’s close: ANAC, ARO, BCEI, COSI, CPE, EGY, FXEN, HOGS, KKD, MCP, OMPI, STEC, ULTA, ZUMZ Comment! [Earnings]
- Thursday, November 1, 2012, 6:09 PM Obagi Medical Products (OMPI): Q3 EPS of $0.16 beats by $0.03. Revenue of $29.1M (+3.6% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
-
- View all 0 replies
-
- View all 16 replies
-
-
ipobeans: It's like blackjack... One more hand please? Or Avon. Feel free to join.
-
Scott Matusow
I have a new Seeking Alpha article out which offers some critique about the Obagi ($OMPI) situation at http://seekingalpha.com/a/k18h - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Scott Matusow
Remember $OMPI trading strat I talked about, buy under 12.50, sell near 13 -- If my thesis is correct, refer to my latest YouTube audio - View all 2 replies
-
-
-
Scott Matusow
I sold my 10k of $OMPI reason = short interest 3 out of 4 sessions over 90% = looking to buy back a lot lower. feel shake out coming there - View all 14 replies
-
LEIGHDIST: don't cut ompi sort it's a great co. and someone will buy it, maybe not Avon but i do beleive there will be a buy out. -
-
- View all 0 replies
-
Scott Matusow
Something might be brewing with $OMPI and no, I do not know exactly what it is, and don't know if it's a buy out, looks like accumulation - View all 12 replies
-
gtgtbangbang: new OPO has agreed to pay Koogly a royalty in an amount that is less than one percent of net sales that are sold through the Obagi website -
LATEST REPLIES
-
- View all 16 replies
-
-
ipobeans: It's like blackjack... One more hand please? Or Avon. Feel free to join.
-
Scott Matusow
I sold my 10k of $OMPI reason = short interest 3 out of 4 sessions over 90% = looking to buy back a lot lower. feel shake out coming there - View all 14 replies
-
LEIGHDIST: don't cut ompi sort it's a great co. and someone will buy it, maybe not Avon but i do beleive there will be a buy out.
-
-
Scott Matusow
Remember $OMPI trading strat I talked about, buy under 12.50, sell near 13 -- If my thesis is correct, refer to my latest YouTube audio - View all 2 replies
-
-
-
Scott Matusow
Something might be brewing with $OMPI and no, I do not know exactly what it is, and don't know if it's a buy out, looks like accumulation - View all 12 replies
-
gtgtbangbang: new OPO has agreed to pay Koogly a royalty in an amount that is less than one percent of net sales that are sold through the Obagi website
-
-
- View all 5 replies
-
-
-
Scott Matusow
Did $OMPI appoint an investment banker today to deal with VOCE? check news feed. investment banker, institutional investment relations = ? - View all 25 replies
-
-
-
Scott Matusow
$OMPI continues to look good, charged Money flow, lots of accumulation at these levels. - View all 4 replies
-
dad58: Its like calling the end of the world , if u say keep saying soon , someday u will be right
-
tcbrinkley: Scott, does today's addition of Mark Taylor as Sr VP of Corp Development and Investor Relations change your outlook of OMPI?
-
Scott Matusow
I'm live now at http://bit.ly/wJZkqa come join me for stock talk! $ATRS $PSTI $OMPI and others - View all 2 replies
-
-
-
- View all 15 replies
-
r27: the 671,494 shares at average price of $15.27 was at end of June Qtr (ie, as on 6/30/12)
-
scubastevo80: Phisher - the website lists the June 30 holdings, they won't update for July 31 until around Aug 15. They could have sold out completely.
-
- View all 2 replies
-
-
FortSumter: It's okay, I own some so be assured it will stay right where it is.
-
- View all 10 replies
-
-
Pescoe: Long term is $$. Look fossil. It was 60,s in May, Today is 90,s. Wa...
-
- View all 8 replies
-
kellymg: Is amrn worth holding onto or is earnings going to hurt even more . Comments appreciated
-
-
- View all 1 replies
-
-
- View all 2 replies
-
-
-
Scott Matusow
Think I will be wrong about $OMPI like I was about MCP when everyone was buying it up @ http://bit.ly/wpLeIV ? - View all 10 replies
-
Scott Matusow: Ya, shorts have a reason, if they know something, then were is the put activity? only a few puts bought. very small amount.
-